Elicio Therapeutics grants 64,643 stock options
Elicio Therapeutics, Inc. reported that Executive Vice President, Head of R&D and Chief Medical Officer Christopher Haqq received a grant of 64,643 stock options on July 16, 2026 at an exercise price of $3.20 per share, expiring on July 16, 2036.
Rhea-AI Filing Summary
Elicio Therapeutics, Inc. reported that Executive Vice President, Head of R&D and Chief Medical Officer Christopher Haqq received a grant of 64,643 stock options on July 16, 2026 at an exercise price of $3.20 per share, expiring on July 16, 2036. The options vest 50% on July 16, 2027 and 50% on July 16, 2028, subject to his continued service, and cover 64,643 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 64,643 shares
Grant/Award
1 txn
Insider
Haqq Christopher
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 64,643 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 64,643 contracts (Direct)
Footnotes (1)
- F1. The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Key Figures
Stock options granted: 64,643 shares
Exercise price: $3.20 per share
Expiration date: July 16, 2036
+3 more
6 metrics
Stock options granted
64,643 shares
Stock option award to Christopher Haqq on July 16, 2026
Exercise price
$3.20 per share
Conversion or exercise price of the stock option grant
Expiration date
July 16, 2036
Expiration of the stock option (right to buy) grant
Vesting first tranche
50% on July 16, 2027
First anniversary of the grant date, subject to continued service
Vesting second tranche
50% on July 16, 2028
Second anniversary of the grant date, subject to continued service
Derivative securities held after grant
64,643 options
Total derivative securities following the reported transaction
Key Terms
Stock Option (Right to Buy), exercise price, vesting, grant date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 3.2000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests and becomes exercisable as to 50% of the options"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
grant date financial
"the first anniversary of the grant date, and as to the remaining 50%"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
expiration date financial
"expiration_date: 2036-07-16"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ELTX report for Christopher Haqq in this Form 4?
Christopher Haqq received a grant of 64,643 stock options for Elicio Therapeutics (ELTX) on July 16, 2026. The options have a $3.20 exercise price, expire on July 16, 2036, and vest in two equal annual installments starting in 2027.
What is the exercise price of the stock options granted to Christopher Haqq at ELTX?
The stock options granted to Christopher Haqq carry an exercise price of $3.20 per share. They relate to 64,643 shares of Elicio Therapeutics common stock and become exercisable in two 50% tranches in 2027 and 2028, subject to his continued service.
When do the ELTX stock options granted to Christopher Haqq vest?
The options vest in two equal installments: 50% on July 16, 2027 and the remaining 50% on July 16, 2028. Vesting is conditioned on Christopher Haqq’s continued service to Elicio Therapeutics through each applicable vesting date.
When do Christopher Haqq’s newly granted ELTX stock options expire?
The stock options granted to Christopher Haqq have an expiration date of July 16, 2036. If not exercised by that date, the right to buy 64,643 shares of Elicio Therapeutics common stock at $3.20 per share will lapse.
Were the ELTX stock option grants to Christopher Haqq made under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 plan checkbox was not marked, meaning this reported stock option grant was not designated as being made pursuant to a Rule 10b5-1 trading arrangement for Elicio Therapeutics (ELTX).
AI-generated analysis. How Rhea-AI works. Not financial advice.
